Belimumab for the treatment of systemic lupus erythematosus

  title={Belimumab for the treatment of systemic lupus erythematosus},
  author={N Jordan and David D'cruz},
  journal={Expert Review of Clinical Immunology},
  pages={195 - 204}
  • N. Jordan, D. D'cruz
  • Published 16 January 2015
  • Medicine, Biology
  • Expert Review of Clinical Immunology
Given their pivotal role in autoantibody production, B-cells have become an attractive therapeutic target in systemic lupus erythematosus (SLE). Belimumab, a fully human monoclonal antibody against B lymphocyte stimulator (BLyS), a B-cell survival factor, was licensed in 2011 for the treatment of autoantibody-positive SLE. The BLISS-52 and BLISS-76 Phase III trials successfully demonstrated that belimumab (10 mg/kg) with standard therapy significantly decreased disease activity in SLE patients… 

Belimumab: A Review in Systemic Lupus Erythematosus

Treatment with IV or SC belimumab plus standard therapy was effective in terms of reducing overall disease activity and reducing the incidence and severity of flares, without worsening of patients’ overall condition or the development of significant disease activity in new organ systems.

The Role of Belimumab in Systemic Lupus Erythematosis: A Systematic Review

Belimumab appears to be efficacious and generally well-tolerated in the treatment of SLE as compared to other drugs, and the long-term use of belimumab combined with standard therapy showed a low incidence of organ damage.

Targeted Therapies in SLE

  • B. HoyerT. Dörner
  • Biology, Medicine
    Dubois' Lupus Erythematosus and Related Syndromes
  • 2019

B Cell-Based Treatments in SLE: Past Experience and Current Directions

Focusing specifically on autoreactive instead of non-specifically altering/depleting lupus, B cell depletion with rituximab is indeed employed worldwide, particularly in standard treatment refractory l upus, with promising results.

BAFF level increased in patients with autoimmune hemolytic anemia.

Serum levels of BAFF in AIHA patients were significantly higher than in healthy subjects, especially for those of IgG(+)C3(+) DAT result, and this might lead to a new approach of AIHA treatment.

Therapeutic targeting of BET protein BRD4 delays murine lupus.

Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis

A correlation between BAFF and the PI3K/Akt/mTOR signaling pathway is revealed, and it is hypothesized that they are involved in the pathogenesis of LN.

Serum BAFF and APRIL levels in patients with autoimmune hemolytic anemia and their clinical significance

Serum levels of BAFF and APRIL potentially represents a useful tool for the assessment of AIHA disease activity and progression and may reflect the clinical activity of this disease.

Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management.

To optimize treatment, it is important that a rheumatologist coordinate closely with the patient's family physician to improve chronic care as well as preventive health services.



Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

Belimumab was well tolerated and reduced peripheral B-cell levels in SLE patients and these data support further studies of belimumab in autoimmune disorders.

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Belimumab treatment improved overall SLE disease activity in the most common musculoskeletal and mucocutaneous organ domains and less worsening occurred in the haematological, immunological and renal domains.

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Rituximab therapy appears to be safe for the treatment of SLE and holds significant therapeutic promise, at least for the majority of patients experiencing profound B cell depletion.

An open study of B lymphocyte depletion in systemic lupus erythematosus.

This study provides sufficient evidence for the safety and possible efficacy of B lymphocyte depletion therapy in SLE to justify a formal controlled trial.

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

In this open study of patients who had failed conventional immunosuppressive therapy, considerable utility in the use of B-cell depletion has been demonstrated and data provide strong support for the performance of a full double blind control trial.

Novel evidence-based systemic lupus erythematosus responder index.

This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.

A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab

Based on the patient's clinically mild SLE and the timing of symptom onset, belimumab likely played a key role in the development of PML and careful monitoring for this potentially fatal adverse effect is warranted.

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.

Patients with SLE with an expanded autoantibody profile and raised BLyS levels at baseline had shorter clinical responses to BCDT, which suggests that treatment regimens beyond B CDT may be necessary to induce long-lasting clinical remissions in these individuals.